Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Next Generation of CAR-T: AZD0120 Dual BCMA/CD19 CAR-T w/ Rapid Manufacturing for Myeloma | EHA 2026
HealthTreeDescription
Can the next generation of CAR-T therapy improve outcomes while reducing manufacturing time? At EHA 2026, investigators presented new data on AZD0120, an innovative dual-targeting CAR-T therapy designed to attack both BCMA and CD19 in patients with relapsed or refractory multiple myeloma.
In this video, we explore the latest results from this early clinical study, including safety, response rates, durability of responses, and the potential advantages of targeting two antigens simultaneously. We also discuss AZD0120’s next-generation manufacturing platform, which aims to shorten vein-to-vein time and make CAR-T therapy available to patients more quickly.
If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu
For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.